Akshat Jain Explores a New Blood Journals Study on the Bleeding Burden in Type 1 VWD
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared on LinkedIn:
”Novel Bispecific Nanobody
New study out in Blood Journals Portfolio on addressing the bleeding burden in Type 1 VWD patients and development of novel therapy options for these patients via SubCutanous route!
American Society of Hematology
KB-V13A12 is designed to increase the patient’s own von Willebrand factor (VWF) levels by bridging VWF to albumin, potentially enhancing VWF survival in the bloodstream.
KB-V13A12 is a bispecific nanobody that binds both VWF and albumin, aiming to harness the recycling pathway of albumin to protect and maintain higher circulating VWF levels.
In laboratory experiments, the nanobody efficiently tethered VWF to albumin without interfering with VWF’s ability to bind Factor VIII or function in clot formation.
In VWD type 1 mouse models, a single subcutaneous dose of KB-V13A12 led to a rapid, dose-dependent increase in VWF levels—up to 2.1-fold—for up to two weeks.
This elevation translated to significantly improved bleeding control in treated mice, using established bleeding models.”
Read the full article in Blood.
Article: A bispecific nanobody for the treatment of von Willebrand disease type 1
Authors: Ivan Peyron, Caterina Casari, Geneviève McCluskey, Vincent Licari, Emilie Bocquet, Claire Auditeau, Mélanie Y. Daniel, Stéphanie Roullet, Sophie Susen, Olivier D. Christophe, Peter J. Lenting, Cécile V. Denis
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial
-
Feb 23, 2026, 11:37Charles Okyere Boadu: Blood Donation Helps Lower Your Risk of Stroke and Organ Damage
-
Feb 23, 2026, 11:29Emma Lefrancais: Uncovering A Key Role for The IL-33/ST2 Axis in Platelet Biology with Lucie Gelon
-
Feb 22, 2026, 14:16Ilenia Calcaterra: From Representation to Intellectual Independence in Women in Science
-
Feb 22, 2026, 13:27Pete Stibbs: New AHA and ACC PE Guidelines Finally Align with Real Clinical Practice
-
Feb 22, 2026, 10:39Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
-
Feb 22, 2026, 09:38Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism
-
Feb 22, 2026, 09:22Shiny K. Kajal: Not All Transfusion Reactions Are Immunohematologic Incompatibilities